Disease: Paroxysmal nocturnal hemoglobinuria
- A case of paroxysmal cold hemoglobinuria complicated by latent syphilis
- A case report of pegcetacoplan use for a pregnant woman with paroxysmal nocturnal hemoglobinuria
- A growing panoply of options for patients with paroxysmal nocturnal hemoglobinuria
- A method for selecting P antigen-negative red cell units for patients with paroxysmal cold hemoglobinuria
- A Series of Eight Cases of Pigment Nephropathy: An Obscured Aspect of Acute Kidney Injury
- Abnormal expression of CUX1 influences autophagy activation in paroxysmal nocturnal hemoglobinuria
- Activity and safety of eltrombopag in combination with cyclosporin A as first‑line treatment of adults with severe aplastic anaemia (SOAR): a phase 2, single-arm study
- Acute Necrotizing Pancreatitis Complicated with Paroxysmal Nocturnal Haemoglobinuria: A Case Report
- Advances in research on renal injury in paroxysmal nocturnal
- Ahemolytic PNH (white cell PNH): Clinical features and implications of a distinct phenotype of paroxysmal nocturnal haemoglobinuria
- An Interesting Case of Paroxysmal Nocturnal Hemoglobinuria With Renal Involvement
- Analysis and summary of clinical characteristics of 289 patients with paroxysmal nocturnal hemoglobinuria in Zhejiang Province
- Aplastic Anemia With Thrombosis Following the Administration of Immunosuppressant and Thrombopoietin Receptor Agonist (TPO-RA)
- Applications of Flow Cytometry in Diagnosis and Evaluation of Red Blood Cell Disorders
- Autoimmune Hemolytic Anemias: Classifications, Pathophysiology, Diagnoses and Management
- Biomimetic proteolipid vesicles for reverting GPI deficiency in paroxysmal nocturnal hemoglobinuria
- Burden of illness in Japanese patients with paroxysmal nocturnal hemoglobinuria receiving C5 inhibitors
- C5 inhibition in PNH: still effective and safe
- Case report: Immune pressure on hematopoietic stem cells can drastically expand glycosylphosphatidylinositol-deficient clones in paroxysmal nocturnal hemoglobinuria
- CD59 gene: 143 haplotypes of 22,718 nucleotides length by computational phasing in 113 individuals from different ethnicities
- Challenges in the diagnosis and management of autoimmune hemolytic anemia: A case-based approach. Experience from a tertiary care hospital in the Haryana region
- Classic paroxysmal nocturnal haemoglobinuria presenting with intestinal malabsorption syndrome, acute abdomen and acute kidney injury
- Coagulation and complement crosstalk: molecular mechanisms of complement-mediated diseases
- Cold-antibody Autoimmune Hemolytic Anemia: its Association with Neoplastic Disease and Impact on Therapy
- Comparative clinical efficacy and safety of biosimilar ABP 959 and eculizumab reference product in patients with paroxysmal nocturnal hemoglobinuria
- Comparison of human leukocyte antigen in patients with paroxysmal nocturnal hemoglobinuria of different clone sizes
- Complement inhibition in paroxysmal nocturnal hemoglobinuria: From biology to therapy
- Consensus recommendations for optimising the diagnosis and treatment of paroxysmal nocturnal haemoglobinuria in Singapore
- Cost-Utility Analysis Comparing Pegcetacoplan to Anti-C5 Monoclonal Antibodies in the Treatment of Paroxysmal Nocturnal Hemoglobinuria
- COVID-19 vaccination prevents a more severe course and treatment with complement inhibitors reduce worsening hemolysis during the Omicron pandemic in patients with PNH: a single-center study
- Crovalimab: First Approval
- Danicopan: First Approval
- Development of a target concentration intervention to individualize paroxysmal nocturnal hemoglobinuria treatment with pegcetacoplan
- Diagnostic landscape of first-time cytometric screening for paroxysmal nocturnal hemoglobinuria in Poland in 2013-2022
- Eculizumab for paroxysmal nocturnal hemoglobinuria: Two cases of successful pregnancy outcomes
- Eculizumab in patients with paroxysmal nocturnal hemoglobinuria: a real-world study in China
- Eculizumab Treatment of Massive Hemolysis Occurring in a Rare Co-Existence of Paroxysmal Nocturnal Hemoglobinuria and Myasthenia Gravis
- Editorial: Practical recommendations and consensus for the management of immune mediated hematologic diseases
- Efficacy, Safety and Quality of Life of Pegcetacoplan in Japanese Patients With Paroxysmal Nocturnal Hemoglobinuria Treated Within the Phase 3 PEGASUS Trial
- Erratum: Candida krusei pneumonia in graft-versus-host disease after allogeneic hematopoietic stem cell transplant for paroxysmal nocturnal hemoglobinuria: a case report: erratum
- Evaluation of the impact of two C5 genetic variants on C5-eculizumab complex stability at the molecular level
- Expert consensus on clonal screening and monitoring of complement inhibitor therapy in paroxysmal nocturnal hemoglobinuria (2024)
- Exploring treatment strategies for paroxysmal nocturnal hemoglobinuria: an overview of registered clinical trials
- Factor B inhibitor iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria
- Fatigue Item Response among Hemoglobin-Normalized Patients with Paroxysmal Nocturnal Hemoglobinuria: PEGASUS Trial Results at 16 and 48 Weeks
- Health-related quality of life and influencing factors of patients with paroxysmal nocturnal hemoglobinuria in China
- Hemolysis events in the phase 3 PEGASUS study of pegcetacoplan in patients with paroxysmal nocturnal hemoglobinuria
- HLA-haploidentical stem cell transplantation in children with inherited bone marrow failure syndromes: A retrospective analysis on behalf of EBMT severe aplastic Anemia and pediatric diseases working parties
- How We Interpret Thrombosis with Thrombocytopenia Syndrome?
- Impact of Lactate Dehydrogenase and Hemoglobin Levels on Clinical Outcomes in Patients With Paroxysmal Nocturnal Hemoglobinuria: Results From the National Korean PNH Registry
- Improvements in hematologic markers and decreases in fatigue with pegcetacoplan for patients with paroxysmal nocturnal hemoglobinuria and mild or moderate anemia (hemoglobin 10 g/dL) who had received eculizumab or were naive to complement inhibitors
- Iptacopan and danicopan for paroxysmal nocturnal hemoglobinuria
- Iptacopan: First Approval
- Kidney R2* Mapping for Noninvasive Evaluation of Iron Overload in Paroxysmal Nocturnal Hemoglobinuria
- Kidney Transplantation After Allogeneic Hematopoietic Cell Transplantation
- Laboratory Evaluation of Immune Hemolytic Anemias
- Life-Threatening Recurrence of Paroxysmal Cold Hemoglobinuria in a Child During Influenza A Infection
- Management of acute breakthrough hemolysis with intensive pegcetacoplan dosing in patients with PNH
- Management of paroxysmal nocturnal hemoglobinuria in CALR mutated post-essential thrombocythemia myelofibrosis: A case report
- Manifestation of Pancytopenia Associated with COVID-19 as Paroxysmal Nocturnal Hemoglobinuria (PNH) and Aplastic Anemia (AA)
- Multisite Thrombosis in a Patient with Paroxysmal Nocturnal Hemoglobinuria
- Normalization of Hemoglobin, Lactate Dehydrogenase, and Fatigue in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Pegcetacoplan
- Oral Iptacopan in Paroxysmal Nocturnal Hemoglobinuria
- Oral Iptacopan in Paroxysmal Nocturnal Hemoglobinuria. Reply
- Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria
- Paroxysmal nocturnal hemoglobinuria-related thrombosis in the era of novel therapies: a 2043 patient/years analysis
- Paroxysmal nocturnal hemoglobinuria-related thrombosis in the era of novel therapies: a 2043-patient-year analysis
- Patient-reported outcomes and daily activity assessed with a digital wearable device in patients with paroxysmal nocturnal hemoglobinuria treated with ravulizumab: REVEAL, a prospective, observational study
- Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
- Pharmacokinetics, pharmacodynamics, efficacy, and safety of ravulizumab in pediatric paroxysmal nocturnal hemoglobinuria
- Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria
- Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition
- Population pharmacokinetic, pharmacodynamic and efficacy modeling of SB12 (proposed eculizumab biosimilar) and reference eculizumab
- Pregnancy in acquired bone marrow failure syndromes: Antenatal management and maternal and fetal outcomes
- Real-world experience of pegcetacoplan in paroxysmal nocturnal hemoglobinuria
- Recurrent Venous Thromboembolism in Patients on Anticoagulation: An Update Based on the Revised AWMF S2k Guideline
- Resolution of extravascular hemolysis with oral iptacopan monotherapy in a patient with treatment experienced paroxysmal nocturnal hemoglobinuria (PNH)
- RNA therapeutics for disorders of excretory system
- Role of <em>PIGM</em> and <em>PIGX</em> in glycosylphosphatidylinositol biosynthesis and human health (Review)
- Safety and Efficacy of Pegcetacoplan in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria over 48 Weeks: 307 Open-Label Extension Study
- Safety Profile of Monoclonal Antibodies and Subsequent Drug Developments in the Treatment of Paroxysmal Nocturnal Hemoglobinuria
- Several implications for the pathogenesis and treatment of thrombosis in PNH patients according to multiomics analysis
- Severe breakthrough hemolysis during compassionate use of Pegcetacoplan in paroxysmal nocturnal hemoglobinuria: managing an emergency
- Single-cell sequencing reveals alterations in the differentiation of bone marrow haematopoietic cells in patients with paroxysmal nocturnal haemoglobinuria
- Stable responses to danicopan as add-on to ravulizumab in two patients with paroxysmal nocturnal hemoglobinuria
- Successful haploidentical hematopoietic stem cell transplantation for paroxysmal nocturnal hemoglobinuria with severe pancytopenia developed after long-term aplastic anemia treatment
- The complement model disease paroxysmal nocturnal hemoglobinuria
- The efficacy and safety of eculizumab in patients and the role of C5 polymorphisms
- The histone demethylase JMJD1C regulates CPS1 expression and promotes the proliferation of paroxysmal nocturnal haemoglobinuria clones through cell metabolic reprogramming
- The immunologic abnormalities in patients with paroxysmal nocturnal hemoglobinuria are associated with disease progression
- The inhibition of several components of terminal complement pathway results in C3 binding to PNH red blood cells
- The metabolic fuel of paroxysmal nocturnal haemoglobinuria
- The role of anticomplement therapy in the management of the kidney allograft
- Thrombosis and meningococcal infection rates in pegcetacoplan-treated patients with paroxysmal nocturnal hemoglobinuria in the clinical trial and postmarketing settings
- Thrombosis in PNH: largely gone, but not forgotten
- Transformation of aplastic anemia with paroxysmal nocturnal hemoglobinuria clone to childhood B-cell precursor acute lymphoblastic leukemia
- Treatment Patterns and Healthcare Resource Utilization of Patients With Paroxysmal Nocturnal Hemoglobinuria: A Retrospective Claims Data Analysis
- Triple-fusion protein (TriFu): A potent, targeted, enzyme-like inhibitor of all three complement activation pathways
- Unveiling Immunological Signatures and Predictors of Response to Immunosuppressive Therapy in Acquired Aplastic Anaemia"
- What is the role of complement in bystander hemolysis? Old concept, new insights